Gilead’s Remdesivir drug, aimed at COVID-19 prevention, has shown good results on macaque monkeys infected with lung disease. Remdesivir is the first drug to show improvement in COVID-19 in human trials and hence it is being closely watched. In India, Gilead has licensed Cipla, Jubilant Life and Hetero Drugs to manufacture Remdesivir for emergency use. It was observed that macaque monkeys that received Remdesivir did not show signs of respiratory disease and also showed.